{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:02:39Z","timestamp":1792015359565,"version":"4.4.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Japan Agency for Medical Reserch and Development","award":["JP21ck0106650"],"award-info":[{"award-number":["JP21ck0106650"]}]},{"name":"Japan Agency for Medical Reserch and Development","award":["JP24ck0106912"],"award-info":[{"award-number":["JP24ck0106912"]}]},{"DOI":"10.13039\/501100001691","name":"Grants-in-Aid for Scientific Research","doi-asserted-by":"crossref","award":["JP22K07240"],"award-info":[{"award-number":["JP22K07240"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Keiryokai Research Foundation","award":["149"],"award-info":[{"award-number":["149"]}]},{"name":"Keiryokai Research Foundation","award":["152"],"award-info":[{"award-number":["152"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s10120-025-01647-1","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T08:02:19Z","timestamp":1753171339000},"page":"1201-1212","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Assessing efficacy of anti-glypican-1 antibody\u2013drug conjugate as potential therapeutic approach for gastric cancer"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2335-340X","authenticated-orcid":false,"given":"Yuji","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Serada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Kawabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Obata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihito","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Funajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuji","family":"Naka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"1647_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1647_CR2","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1005\u201320.","journal-title":"Ann Oncol"},{"key":"1647_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27\u201340.","journal-title":"Lancet"},{"key":"1647_CR4","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/s41586-022-04508-4","volume":"603","author":"K Shitara","year":"2022","unstructured":"Shitara K, Ajani JA, Moehler M, Garrido M, Gallardo C, Shen L, et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022;603:942\u20138.","journal-title":"Nature"},{"key":"1647_CR5","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S1470-2045(13)70549-7","volume":"15","author":"HE Ford","year":"2014","unstructured":"Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014;15:78\u201386.","journal-title":"Lancet Oncol"},{"key":"1647_CR6","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","volume":"34","author":"J Li","year":"2016","unstructured":"Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, et al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016;34:1448\u201354.","journal-title":"J Clin Oncol"},{"key":"1647_CR7","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/S1470-2045(18)30739-3","volume":"19","author":"K Shitara","year":"2018","unstructured":"Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, et al. Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19:1437\u201348.","journal-title":"Lancet Oncol"},{"key":"1647_CR8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ejca.2022.01.015","volume":"165","author":"S Lorenzen","year":"2022","unstructured":"Lorenzen S, Thuss-Patience P, Pauligk C, G\u00f6kkurt E, Ettrich T, Lordick F, et al. FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel - results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO. Eur J Cancer. 2022;165:48\u201357.","journal-title":"Eur J Cancer"},{"key":"1647_CR9","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy. Signal Transduct Target Ther. 2022;7:93.","journal-title":"Signal Transduct Target Ther"},{"key":"1647_CR10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/bjc.2016.183","volume":"115","author":"H Hara","year":"2016","unstructured":"Hara H, Takahashi T, Serada S, Fujimoto M, Ohkawara T, Nakatsuka R, et al. Overexpression of glypican-1 implicates poor prognosis and their chemoresistance in oesophageal squamous cell carcinoma. Br J Cancer. 2016;115:66\u201375.","journal-title":"Br J Cancer"},{"key":"1647_CR11","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1172\/JCI200113712","volume":"108","author":"J Filmus","year":"2001","unstructured":"Filmus J, Selleck SB. Glypicans: proteoglycans with a surprise. J Clin Invest. 2001;108:497\u2013501.","journal-title":"J Clin Invest"},{"key":"1647_CR12","doi-asserted-by":"publisher","first-page":"C846","DOI":"10.1152\/ajpcell.00290.2021","volume":"321","author":"J Pan","year":"2021","unstructured":"Pan J, Ho M. Role of glypican-1 in regulating multiple cellular signaling pathways. Am J Physiol Cell Physiol. 2021;321:C846\u201358.","journal-title":"Am J Physiol Cell Physiol"},{"key":"1647_CR13","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.75545","volume":"11","author":"C Sparn","year":"2022","unstructured":"Sparn C, Dimou E, Meyer A, Saleppico R, Wegehingel S, Gerstner M, et al. Glypican-1 drives unconventional secretion of fibroblast growth factor 2. Elife. 2022;11: e75545.","journal-title":"Elife"},{"key":"1647_CR14","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1002\/cam4.1064","volume":"6","author":"H Lu","year":"2017","unstructured":"Lu H, Niu F, Liu F, Gao J, Sun Y, Zhao X. Elevated glypican-1 expression is associated with an unfavorable prognosis in pancreatic ductal adenocarcinoma. Cancer Med. 2017;6:1181\u201391.","journal-title":"Cancer Med"},{"key":"1647_CR15","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3892\/ol.2020.12058","volume":"20","author":"G Chen","year":"2020","unstructured":"Chen G, Wu H, Zhang L, Wei S. High glypican-1 expression is a prognostic factor for predicting a poor clinical prognosis in patients with hepatocellular carcinoma. Oncol Lett. 2020;20:197.","journal-title":"Oncol Lett"},{"key":"1647_CR16","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1158\/1535-7163.MCT-21-0015","volume":"20","author":"K Yokota","year":"2021","unstructured":"Yokota K, Serada S, Tsujii S, Toya K, Takahashi T, Matsunaga T, et al. Anti-glypican-1 antibody-drug conjugate as potential therapy against tumor cells and tumor vasculature for glypican-1-positive cholangiocarcinoma. Mol Cancer Ther. 2021;20:1713\u201322.","journal-title":"Mol Cancer Ther"},{"key":"1647_CR17","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.neo.2021.07.006","volume":"23","author":"E Munekage","year":"2021","unstructured":"Munekage E, Serada S, Tsujii S, Yokota K, Kiuchi K, Tominaga K, et al. A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma. Neoplasia. 2021;23:939\u201350.","journal-title":"Neoplasia"},{"key":"1647_CR18","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1158\/0008-5472.CAN-15-1795","volume":"76","author":"F Li","year":"2016","unstructured":"Li F, Emmerton KK, Jonas M, Zhang X, Miyamoto JB, Setter JR, et al. Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models. Cancer Res. 2016;76:2710\u20139.","journal-title":"Cancer Res"},{"key":"1647_CR19","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1172\/JCI120481","volume":"128","author":"C Szot","year":"2018","unstructured":"Szot C, Saha S, Zhang XM, Zhu Z, Hilton MB, Morris K, et al. Tumor stroma-targeted antibody-drug conjugate triggers localized anticancer drug release. J Clin Invest. 2018;128:2927\u201343.","journal-title":"J Clin Invest"},{"key":"1647_CR20","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1158\/1535-7163.MCT-21-0335","volume":"20","author":"S Tsujii","year":"2021","unstructured":"Tsujii S, Serada S, Fujimoto M, Uemura S, Namikawa T, Nomura T, et al. Glypican-1 is a novel target for stroma and tumor cell dual-targeting antibody-drug conjugates in pancreatic cancer. Mol Cancer Ther. 2021;20:2495\u2013505.","journal-title":"Mol Cancer Ther"},{"key":"1647_CR21","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/s41416-020-0781-2","volume":"122","author":"T Nishigaki","year":"2020","unstructured":"Nishigaki T, Takahashi T, Serada S, Fujimoto M, Ohkawara T, Hara H, et al. Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer. Br J Cancer. 2020;122:1333\u201341.","journal-title":"Br J Cancer"},{"key":"1647_CR22","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1158\/1535-7163.MCT-15-0036","volume":"14","author":"R Chen","year":"2015","unstructured":"Chen R, Hou J, Newman E, Kim Y, Donohue C, Liu X, et al. CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin. Mol Cancer Ther. 2015;14:1376\u201384.","journal-title":"Mol Cancer Ther"},{"key":"1647_CR23","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/jnci\/djz035","volume":"111","author":"MJ Birrer","year":"2019","unstructured":"Birrer MJ, Moore KN, Betella I, Bates RC. Antibody-drug conjugate-based therapeutics: state of the science. J Natl Cancer Inst. 2019;111:538\u201349.","journal-title":"J Natl Cancer Inst"},{"key":"1647_CR24","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41416-018-0202-y","volume":"119","author":"N Kemi","year":"2018","unstructured":"Kemi N, Eskuri M, Herva A, Lepp\u00e4nen J, Huhta H, Helminen O, et al. Tumour-stroma ratio and prognosis in gastric adenocarcinoma. Br J Cancer. 2018;119:435\u20139.","journal-title":"Br J Cancer"},{"key":"1647_CR25","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1007\/s00535-017-1379-1","volume":"53","author":"C Peng","year":"2018","unstructured":"Peng C, Liu J, Yang G, Li Y. The tumor-stromal ratio as a strong prognosticator for advanced gastric cancer patients: proposal of a new TSNM staging system. J Gastroenterol. 2018;53:606\u201317.","journal-title":"J Gastroenterol"},{"key":"1647_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2024.100982","volume":"50","author":"S Uchida","year":"2024","unstructured":"Uchida S, Serada S, Suzuki Y, Funajima E, Kitakami K, Dobashi K, et al. Glypican-1-targeted antibody-drug conjugate inhibits the growth of glypican-1-positive glioblastoma. Neoplasia. 2024;50: 100982.","journal-title":"Neoplasia"},{"key":"1647_CR27","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1038\/s41467-021-23793-7","volume":"12","author":"CM Yamazaki","year":"2021","unstructured":"Yamazaki CM, Yamaguchi A, Anami Y, Xiong W, Otani Y, Lee J, et al. Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. Nat Commun. 2021;12:3528.","journal-title":"Nat Commun"},{"key":"1647_CR28","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382:2419\u201330.","journal-title":"N Engl J Med"},{"key":"1647_CR29","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1002\/cac2.12214","volume":"41","author":"Z Peng","year":"2021","unstructured":"Peng Z, Liu T, Wei J, Wang A, He Y, Yang L, et al. Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study. Cancer Commun (Lond). 2021;41:1173\u201382.","journal-title":"Cancer Commun (Lond)"},{"key":"1647_CR30","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s10120-021-01168-7","volume":"24","author":"Y Xu","year":"2021","unstructured":"Xu Y, Wang Y, Gong J, Zhang X, Peng Z, Sheng X, et al. Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors. Gastric Cancer. 2021;24:913\u201325.","journal-title":"Gastric Cancer"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-025-01647-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-025-01647-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-025-01647-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:03:21Z","timestamp":1784678601000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-025-01647-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1647"],"URL":"https:\/\/doi.org\/10.1007\/s10120-025-01647-1","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"assertion":[{"value":"7 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing financial interests or personal relationships that may have influenced the work reported in this study.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal studies: All animal studies were conducted in accordance with the ARRIVE guideline and approved by the Ethics Committee for Animal Experiments at Iwate Medical University (03-004) ensuring compliance with institutional guidelines. Human studies: This study was conducted in accordance with the Declaration of Helsinki, and all patients were prospectively enrolled and they provided written informed consent before tissue sampling based on a protocol approved by the Institutional Review Board of Osaka University (Approval Number: 08226-5). Additionally, this study was conducted as an ancillary research project and was independently approved by the Institutional Review Board of Osaka University (Approval Number: 20443).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}